ZOLL WatchPAT 400 Gains FDA Clearance to Add Home Polysomnography Channels
By SR Edit Staff 597 views
PolySense accessories let the WatchPAT 400 measure up to 11 channels at home, closing the gap between routine apnea testing and full PSG.

The gap between a home sleep apnea test and a full polysomnogram has closed a little further. ZOLL Itamar has received FDA 510(k) clearance for PolySense, a set of accessories that turn its WatchPAT 400 from a standard home sleep apnea test (HSAT) device into one capable of home polysomnography (home PSG). The device will be available to US customers in early January 2027. A 510(k) clearance means the FDA found the accessories substantially equivalent to a device already on the market. That's a narrower bar than a full pre-market approval, so the review focused on whether the add-on is safe and works as intended, not on proving new clinical benefit.
For practices running home-based sleep testing, that shift is meaningful. Until now, when a physician suspected more than straightforward sleep apnea, something that might involve a broader range of diagnostic possibilities, a full lab-based polysomnogram was effectively the only path. Patients had to spend a night in a sleep lab. That requirement has long been a bottleneck, not because the lab study is wrong, but because labs have limited capacity, scheduling waits, and an unfamiliar bedroom that can disturb sleep. PolySense is the first time a home study can cover that advanced territory on a platform clinicians already know.
What the accessories actually do
The design is built around self-application. Head, cardiac, and leg patches record EEG, EOG, EMG, ECG, and leg movement, with interchangeable modules that snap onto the WatchPAT 400. EEG tracks brain activity, EOG captures eye movements that help define sleep stages, EMG measures muscle tone, and ECG records heart rhythm. Leg movement sensors pick up the repetitive limb motions that can fragment sleep. The patient applies everything at home, and a physician gets immediate access to results when the test is complete, with no lab technician and no overnight facility booking.
Self-application is the bold part, and it's also the riskiest. Electrode placement is where home studies most often go wrong, and a poorly seated patch can produce noisy or unusable data. (And this is the part most people overlook: a failed home study isn't just an inconvenience. It can mean a repeat test, a delayed diagnosis, and a frustrated patient.) The manufacturer's design choices here will matter as much as the sensor quality itself.
The scalability is the key point here. One device now covers a routine HSAT at the low end and advanced testing at the high end. With the full PolySense kit, the WatchPAT 400 can measure up to 11 channels and analyze 9 parameter categories, referenced by the AMA CPT Assistant and effective January 1, 2027. Channel count alone doesn't tell you diagnostic quality, though. What counts is whether the signals are clean and whether the analysis covers the questions the physician is actually asking. Same box, different ceiling.
Why it matters to providers
Alan Schwartz, MD, of the University of Maryland Medical System's pulmonary critical care and sleep medicine division, put it plainly. Some of his patients need an advanced sleep study to work through several diagnostic possibilities rather than a standard home test. Until now, that required a full lab-based PSG. With the PolySense accessories, he can run that study at home and choose the right level of testing per patient without sending everyone to a lab. His framing is clinical rather than promotional, and that's the perspective worth weighing most.
Shiri Shneorson, president of ZOLL's Itamar division, framed it as a direct response to customer demand. Practices wanted a simple way to offer advanced sleep testing at home, and the self-application design helps them run more home PSG studies efficiently on a platform they already use. The company built it from that feedback and is positioning flexible acquisition options for the US market. Customer-driven development is common in medical devices, and it's usually a good sign. Still, it's a vendor's account of its own product, and it's fair to read it that way.
What this means for you
If you're working in a sleep practice, the most immediate question is workflow. A platform your staff already uses is easier to adopt than a new system, and that lowers the learning curve. You'll still need to think through patient onboarding, how you'll confirm patch placement, and how you'll handle a study that comes back with gaps. None of that is automatic just because the hardware is cleared.
For patients, the appeal is obvious. Sleeping in your own bed, with your own routine, is a better starting point for a study than a night wired up in an unfamiliar room. But the benefit depends on the clinician ordering the right test for the right person. A home study isn't a shortcut around clinical judgment, and it won't replace a lab night for every case. What this means for you as a patient is simple: ask your physician why a particular test was chosen, and what it will and won't capture.
What to watch next
Two things will define the real-world impact. First, the 2027 coding changes. The 11-channel, 9-parameter capability is tied to new CPT codes taking effect on January 1, 2027, so the device launch and the reimbursement framework arrive together. Practices will need their billing teams ready, and the details of how payers respond are the kind of thing that's hard to call from here. Second, adoption. The promise is a home study that covers more ground than apnea alone, but whether clinicians will route more advanced cases to home PSG versus sending them to a lab will depend on whether the channel depth matches the diagnostic questions they actually face.
My read is that this matters most for the patients who were previously stuck choosing between an inadequate home apnea test and a lab night they couldn't easily get. That group has been underserved, and this is more significant than it looks at first glance. The next few months of provider feedback will show whether home PSG becomes the default first-line advanced test or stays a niche add-on. Big if, and the answer will come from clinics, not press releases.
